In view of the possible role of ADAM17 in ovarian cancer, in cisplatin resistance and in the induction of angiogenesis pathways alternative to VEGF, in this study we investigated the ADAM17 protein expression by immunohistochemistry (IHC) in tissue microarrays (TMAs) from the cohort of ovarian cancer patients enrolled in the MITO16A/MANGO-OV2 clinical trial. The gene discussed is ADAM17; the disease is ovarian carcinoma.